MedPath

Effects of combination therapy with sitagliptin and metformin on glycemic control-related factor, beta-cell function, lipid profile, and kidney function in patients with type 2 diabetes.

Not Applicable
Conditions
Type 2 diabetes
Registration Number
JPRN-UMIN000013509
Lead Sponsor
Misaki naika clinic
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) type 1 diabetes 2) had ketosis or coma within 6 month 3) after severe infection, operation or injure 4) impaired renal function (Serum Cr>1.5mg/dL for male,>1.3mg/dL for female) 5) is pregnancy or chance of pregnant 6) Under treatment by other anti-diabetic drugs 7) Has allergy to DPP-4 inhibitor 8) Patient who was considered to be appropriate to this study by attending physician

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change rate of HbA1c
Secondary Outcome Measures
NameTimeMethod
Chage rate of fasting blood glucose, active GLP-1, proinsulin / insulin ratio (P / I), HOMA-beta, HOMA-R, general lipid, RLP-C, LPL, HPLC lipoprotein quantitative analysis (H) , urinary albumin (ACR), cystatin C, L-type fatty acid binding protein (L-FABP), liver function.
© Copyright 2025. All Rights Reserved by MedPath